Skip to content

The median effective dose of sufentanil to induce respiratory depression in combination with dezocine

The median effective dose of sufentanil combined with dezocine to induce respiratory depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059399
Enrollment
Unknown
Registered
2022-04-29
Start date
2022-04-14
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Espiratory depression caused by sufentanil

Interventions

SD:sufentanil combination with dezocine
CG:Sufentanil alone

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Elective general anesthesia surgery; 2. ASA I-II; 3. Aged 18-60 years; 4. BMI 18-24 kg/m2; 5. No history of mental illness or long-term use of psychiatric drugs (dementia, schizophrenia), history of chronic analgesic use, history of alcoholism; 6. No asthma, chronic bronchitis and other respiratory diseases; 7. No obvious abnormality was found in respiratory and circulatory and liver and kidney functions; 8. No obvious endocrine and metabolic diseases; 9. Preoperative arterial blood gas analysis was normal.

Exclusion criteria

Exclusion criteria: 1. With a history of chronic cough; 2. Any sign of upper respiratory infection; 3. A history of chronic pain; 4. Asthma; 5. Smoking; 6. Prior treatment with angiotensin-converting enzyme inhibitors, with a history of bronchodilator or steroid therapy; 7. Allergic to narcotic drugs.

Design outcomes

Primary

MeasureTime frame
Median effective dose;Respiratory rate;Apnea time;

Secondary

MeasureTime frame
Observer’s assessment of alertness/sedation;Blood pressure;Heart rate;Pulse Oxygen Saturation;PETCO2;

Countries

China

Contacts

Public ContactXu Guanghong

The First Affiliated Hospital of Anhui Medical University

xuguanghong2004@163.com+86 13856949535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026